The Future of Heart Health is AI: Voythos Brings New Outcomes to Aortic Disease
Joe Makoid is the Co-Founder and CEO at Voythos, a seed-stage AI informatics company building multimodal machine learning models to predict life-threatening complications in aortic disease. He has a background in energy and robotics sales.
Connect with Joe:
LinkedIn: Joe Makoid
Websites: Voythos | voythos.io
🌟 Resources & Links
- Explore past episodes: Forging the Future Episodes
- Learn about Softeq: com
Stay inspired and ahead of the curve by subscribing to Forging the Future. Share your thoughts on this episode with the hashtag #ForgingTheFuture or tag us online!
🎧 Episode Highlights
- [00:00] Podcast Begins
- [01:28] Gut Feelings, Heart Predictions: Complexities of the aorta & limits of surgeons
- [05:14] Where Does Voythos Come In? Understanding when AI helps surgeons the most
- [11:26] Training AI on Aortic Data: Challenges, reliability & availability of patient data
- [14:57] Sales Background in an Entrepreneur Role: The impact of founder-led sales
- [18:56] What About Regulation? Hurdles & helpful aspects of highly regulated medtech
- [23:46] Next Steps for Voythos: Predictions for an AI-friendlier healthcare system
🔑 Key Takeaways
- Beyond the “Gut Feeling”? “The aorta is incredibly complex, and that complexity is magnified by the high stakes predictions that need to be made,” Joe explains, outlining the gap presented between a surgeon’s knowledge and their ability to act on a prediction. “Surgeons are incredibly brilliant, but what we’re solving for is the limitations of the human brain. There are only so many patterns we can process.”
- MultiModal Machine Learning: A patient’s risk for aortic disease and complications from it can vary greatly depending on imaging, demographic data, and health records. “We’ve developed an architect that can fuse these data points together, understand the contextual relationship, and start to predict,” Joe says about Voythos’ developing tech.
- What About Risk & Regulations? “Our product will have to go through FDA approval,” Joe admits, elaborating that for medical startups, it can be hard to find investors willing to unwrite an FDA risk. “I believe what we’re building should have a third-party stamp of approval, we’re helping surgeons make very high stakes decisions.”
👤 Guest Spotlight
Joe Makoid:
Joe Makoid is the Co-Founder and CEO at Voythos, a seed-stage AI informatics company building multimodal machine learning models to predict life-threatening complications in aortic disease. He has a background in energy and robotics sales.
You may be interested in:
